Literature DB >> 21632841

Costs and consequences of immunosuppressive therapy in children with aplastic anemia.

Evan B Shereck, Rebecca J Deyell, Peter Kurre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21632841      PMCID： PMC3105637          DOI： 10.3324/haematol.2011.044917

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Danazol as first-line therapy for aplastic anemia.

Authors:  José Carlos Jaime-Pérez; Perla R Colunga-Pedraza; Cynthia D Gómez-Ramírez; César H Gutiérrez-Aguirre; Olga G Cantú-Rodríguez; Luz C Tarín-Arzaga; David Gómez-Almaguer
Journal:  Ann Hematol       Date:  2011-01-29       Impact factor: 3.673

Review 2.  Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going.

Authors:  Antonio M Risitano
Journal:  Br J Haematol       Date:  2010-12-01       Impact factor: 6.998

Review 3.  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Authors:  Ronit Gurion; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Moshe Yeshurun; Ofer Shpilberg; Pia Raanani
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

4.  Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.

Authors:  Rodrigo T Calado; William T Yewdell; Keisha L Wilkerson; Joshua A Regal; Sachiko Kajigaya; Constantine A Stratakis; Neal S Young
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

5.  Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.

Authors:  Jessica M Valdez; Phillip Scheinberg; Olga Nunez; Colin O Wu; Neal S Young; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

6.  Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia.

Authors:  H Yagasaki; Y Takahashi; A Hama; K Kudo; N Nishio; H Muramatsu; M Tanaka; N Yoshida; K Matsumoto; N Watanabe; K Kato; K Horibe; S Kojima
Journal:  Bone Marrow Transplant       Date:  2010-02-01       Impact factor: 5.483

Review 7.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

8.  [Prognostic factors of immunosuppressive therapy in children acquired aplastic anemia].

Authors:  Shu-chun Wang; Xiao-juan Chen; Yao Zou; Wen-yu Yang; Tian-feng Liu; Li Zhang; Yu-mei Chen; Ye Guo; Xiao-fan Zhu
Journal:  Zhonghua Er Ke Za Zhi       Date:  2009-08

9.  Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Neal S Young
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

Review 10.  Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia.

Authors:  M Führer
Journal:  Bone Marrow Transplant       Date:  2008-10       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.